Цефиксим. Клиническая эффективность при обострении нетяжелой хронической обструктивной болезни легких и влияние на развитие рецидивов заболевания. Наблюдательная программа

1. American Thoracic Society. Chronic bronchitis, asthma, and pulmonary emphysema: a statement by the Committee on Diagnostic Standards for Nontuberculous Respiratory Diseases. Am review respir diseases 1962; 85: 762–8.
2. Fletcher C, Peto R. Natural history of chronic constriction of respiratory tract (author's transl). Przeglad lekarski 1978; 35: 747–52.
3. Seemungal TA, Hurst JR, Wedzicha JA. Exacerbation rate, health status and mortality in COPD – a review of potential interventions. Int J Chron Obstruct Pulmon Dis 2009; 4: 203–23.
4. Vestbo J, Hurd SS, Agusti AG et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary. Am J Respir Critical Care Med 2013; 187: 347–65.
5. Lindenauer PK, Pekow P, Gao S et al. Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2006; 144: 894–903.
6. Anthonisen NR, Manfreda J, Warren CP et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204.
7. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane database of systematic reviews (Online) 2006: CD004403.
8. The OMBIRT Consensus Panel. Outpatient Management of Bacterial Infections in the Lower Respiratory Tract (OMBIRT): Diagnosis, Evaluation, and Antibiotic Selection in the Primary Care Setting. Atlanta, Ga: American Health Consultants, 2001.
9. Wilkinson TM, Donaldson GC, Hurst JR et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Critical Care Med 2004; 169: 1298–303.
10. Seemungal TAR, Harper-Owen R, Bhowmik A et al. Respiratory viruses, symptoms and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Critical Care Med 2001; 164: 1618–23.
11. Rohde G, Wiethege A, Borg I et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax 2003; 58: 37–42.
12. Qiu Y, Zhu J, Bandi V et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Critical Care Med 2003; 168: 968–75.
13. Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638–45.
14. Alvarez-Sala JL, Kardos P, Martinez-Beltran J et al. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. Antimicrob Agents Chemother 2006; 50: 1762–7.
15. Fogarty CM, Bettis RB, Griffin TJ et al. Comparison of a 5 day regimen of cefdinir with a 10 day regimen of cefprozil for treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemotner 2000; 45: 851–8.
16. Miravitlles M, Espinosa C, Fernandez-Laso E et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999; 116: 40–6.
17. Ko WC, Paterson DL, Sagnimeni AJ et al. Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns. Emerg Infect Dis 2002; 8: 160–6.
18. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999–2005 гг.: результаты многоцентровых проспективных исследований ПеГАС–I и ПеГАС–II. Клин. микробиология и антимикроб. химиотерапия. 2006; 8: 33–47.
19. Lorenz J, Steinfeld P, Drath L et al. Efficacy and tolerability of 5 vs 10 day cefixime therapy in acute exacerbations of chronic bronchitis. Clin Drug Invest 1998; 15: 13–20.
20. Neu HC, Chick TW. Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections. Chest 1993; 104: 1393–9.
21. Quintiliani R. Cefixime in the treatment of patients with lower respiratory tract infections: results of US clinical trials. Clin Ther 1996; 18: 373–90; discussion 2.
22. National Heart, Lung and Blood Institute, World Health Organization. Workshop report: global strategy for the diagnosis, management, and prevention of COPD: updated 2007. Available from URL: http://www.goldcopd.org.
23. Mandell LA, Wunderink RG, Anzueto A et al. Infectious diseases society of america/american thoracic society consensus guidelines on the management of community – acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl. 2): S27–72.
24. Chow AW, Hall CB, Klein JO et al. Evaluation of new anti–infective drugs for the treatment of respiratory tract infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15 (Suppl. 1): S62–88.
25. Chodosh S. Clinical significance of the infection – free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest 2005; 127: 2231–6.
26. Dimopoulos G, Siempos, II, Korbila IP et al. Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials. Chest 2007; 132: 447–55.
27. Destache CJ, Dewan N, O'Donohue WJ et al. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Аntimicrob Chemother 1999; 43 (Suppl. A): 107–13.
28. Georgopoulos A, Borek M, Ridl W. Randomized, double–blind, double–dummy study comparing the efficacy and safety of amoxicillin 1 g bd with amoxycillin 500 mg tds in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 2001; 47: 67–76.
29. Canut A, Martin-Herrero JE, Labora A, Maortua H. What are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? A therapeutic outcomes model. J Antimicrob Chemother 2007; 60: 605–12.
30. White AJ, Gompertz S, Bayley DL et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003; 58: 680–5.
31. Chodosh S, McCarty J, Farkas S et al. Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Clin Infect Dis 1998; 27: 722–9.
32. Zuck P, Petitpretz P, Geslin P et al. Bacteriological eradication of Streptococcus pneumoniae from patients with acute exacerbations of chronic bronchitis: cefuroxime axetil versus cefixime. Intern J Clin Practice 1999; 53: 437–43.
33. Arthur M, McAdoo M, Guerra J et al. Clinical comparison of cefuroxime axetil with cefixime in the treatment of acute bronchitis. Am J Ther 1996; 3: 622–9.
34. Lieberman D, Schlaeffer F. Once-a-day cefixime versus co-amoxiclav three times daily in the treatment of lower respiratory infections. J Antimicrob Chemother 1995; 35: 354–7.
35. Vogel F, Scholz H, al Nawas B et al. Rational use of oral antibiotics. Findings of an expert commission of the Paul Ehrlich Society for Chemotherapy. Medizinische Monatsschrift fur Pharmazeuten 2002; 25: 193–204.
36. Blumer JL. Pharmacokinetics and pharmacodynamics of new and old antimicrobial agents for acute otitis media. Pediatr Infect Disease J 1998; 17: 1070–5; discussion 99–100.
37. Klepser ME, Marangos MN, Patel KB et al. Clinical pharmacokinetics of newer cephalosporins. Clin Pharm 1995; 28: 361–84.
38. Silber DM, Bohaychuk W, Stout M et al. Pharmacokinetics of cefixime in young and elderly volunteers. Workshop. 15th International Congress of Chemotherapy, Jul 87. Adv Exp Clin Chemother 1988; 1: 18–20.
39. Stone JW, Linong G, Andrews JM, Wise R. Cefixime, in-vitro activity, pharmacokinetics and tissue penetration. J Antimicrob Chemother 1989; 23: 221–8.
40. Baldwin DR, Andrews JM, Ashby JP et al. Concentrations of cefixime in bronchial mucosa and sputum after three oral multiple dose regimens. Thorax 1990; 45: 401–2.
41. Maesen FP, Costongs R, Davies BI. Concentrations of cefixime in bronchial mucosa and sputum. Thorax 1990; 45: 982–3.
42.Wise R. The pharmacokinetics of the oral cephalosporins – a review. J Antimicrob Chemother 1990; 26 (Suppl. E): 13–20.
43. Grellet J, Couraud L, Saux MC, Roche G. Pulmonary diffusion of cefixime in man. Presse Med 1989; 18: 1589–92.
44. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis (Suppl.) 1990; 74: 63–70.
45. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement. CLSI document M100–S17. Waynre, PA: Clinical and Laboratory Standards Institute, 2007.
46. Fenoll A, Robledo O, Lerma M et al. Activity of cefpodoxime and other oral beta-lactams against Haemophilus influenzae and Streptococcus pneumoniae with different susceptibilities to penicillin. Rev Esp Quimioter 2006; 19: 39–44.
47. Kardas P. Non-compliance-some myths, some facts. Casopis Lekaru Ceskych 2004; 143: 556–9; discussion 60.
48. Kardas P. Patient non-compliance as a cause of treatment failure. Pol Merkur Lekarski 2000; 9: 732–5.
49. Garau J, Twynholm M, Garcia-Mendez E et al. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults. J Antimicrob Chemother 2003; 52: 826–36.
50. Henry DC, Riffer E, Sokol WN et al. Randomized double-blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis. Antimicrob Agents Chemother 2003; 47: 2770–4.
51. Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med 2004; 98: 708–20.
52. Arrieta JR, Galgano AS, Sakano E et al. Moxifloxacin vs amoxicillin/clavulanate in the treatment of acute sinusitis. Am J Otolaryngol 2007; 28: 78–82.
53. Poirier R, Chardon H, Beraud A et al. Efficacy and tolerability of pristinamycin vs amoxicillin-clavulanic acid combination in the treatment of acute community-acquired pneumonia in hospitalized adults. Rev Pneumol Clin 1997; 53: 325–31.
54. File TM, Lode H, Kurz H et al. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. Antimicrob Agents Chemother 2004; 48: 3323–31.
55. Neu HC, Wilson AP, Gruneberg RN. Amoxycillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992. J Chemother (Florence, Italy) 1993; 5: 67–93.
56. Siquier B, Sanchez-Alvarez J, Garci-Mendez E et al. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2006; 57: 536–45.
57. Ren X, Liu D, Ding N et al. Safety evaluation of cephalosporins based on utilization and adverse drug events: analysis of two databases in China. Exp Opinion Drug Safety 2012; 11: 689–97.

И.А.Гучев1, Е.В.Сафонова2, А.Н.Цой2 

1. Филиал №4 ФГУ 1586 Окружной военный клинический госпиталь Московского военного округа Минобороны РФ, Смоленск; 2ГКБ №23 им. Медсантруд ДЗ г. Москвы